Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2012

Filed with the SEC on Aug 9, 2012 and accepted by EDGAR at Aug 9, 2012, 16:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2012-04-01 to 2012-06-30$2.0mus-gaap:Revenues
Revenue6 months2012-01-01 to 2012-06-30$4.4mus-gaap:Revenues
Research and development3 months2012-04-01 to 2012-06-30$11.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2012-01-01 to 2012-06-30$21.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2012-04-01 to 2012-06-30−$13.5mus-gaap:OperatingIncomeLoss
Operating income6 months2012-01-01 to 2012-06-30−$26.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2012-04-01 to 2012-06-30$411.0kus-gaap:InterestExpense
Interest expense6 months2012-01-01 to 2012-06-30$844.0kus-gaap:InterestExpense
Net income3 months2012-04-01 to 2012-06-30−$13.8mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income6 months2012-01-01 to 2012-06-30−$27.3mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2012-04-01 to 2012-06-30−$0.23us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2012-01-01 to 2012-06-30−$0.50us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2012-01-01 to 2012-06-30−$25.5mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure6 months2012-01-01 to 2012-06-30$122.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2012-06-30$18.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-06-30$80.4mus-gaap:AssetsCurrent
Total assetsAt period end2012-06-30$122.1mus-gaap:Assets
Current liabilitiesAt period end2012-06-30$12.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-06-30$27.6mus-gaap:Liabilities
Shareholders' equityAt period end2012-06-30$94.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-12-056527. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.